Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 811 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR New on NCI’s Websites for October 2019 October 3, 2019 Rebuilding My Life After Cancer and Intensive Treatment: A Survivor’s Story February 9, 2023 She Faced Breast Cancer At 16 With Little Help From Doctors.... June 21, 2019 New plan unveiled to tackle Scotland’s cancer crisis June 16, 2023 Load more HOT NEWS 120 years of Cancer Research UK: how science transformed survival rates 74 & 75-Year-Old Sweethearts Get Married In ICU In Wake Of... Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm FDA Approves Axicabtagene Ciloleucel for Second-Line Treatment of Large B-Cell Lymphoma
